This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Teelmann, K., Hohbach, C. & Lehmann, H. Arch. Toxicol. 59, 195–200 (1986).
International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (1997). Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Safety/S6_R1/Step4/S6_R1_Guideline.pdf (ICH, 1997).
Bailey, J., Capaldo, T., Conlee, K., Thew, M. & Pippin, J. Nat. Med. 14, 1011–1012; discussion 1012–1013 (2008).
European Medicines Agency. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000240/human_med_001023.jsp&mid=WC0b01ac058001d124 (EMA, 2008).
European Medicines Agency. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000582/human_med_000663.jsp&mid=WC0b01ac058001d124# (EMA, 2006).
Fraser, H.M. & Wulff, C. Reprod. Biol. Endocrinol. 1, 88 (2003).
European Medicines Agency. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/000972/WC500051808.pdf (EMA, 2009).
European Medicines Agency. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/001109/WC500031679.pdf (EMA, 2009).
European Medicines Agency. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000715/WC500043550.pdf (EMA, 2007).
European Medicines Agency. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000353/WC500025264.pdf (EMA, 2005).
European Medicines Agency. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/001037/WC500069735.pdf (EMA, 2009).
European Medicines Agency. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000603/WC500044690.pdf (EMA, 2007).
Acknowledgements
This research is part of Top Institute Pharma project T6-301. P.J.K.v.M. and M.K. performed this work with the TIP grant. The views expressed in this article are the personal views of the authors and are not to be understood or quoted as being made on behalf of or reflecting the position of the Medicines Evaluation Board or any other regulatory agency, or one of its committees or working parties.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
H.S. participated in meetings and publications sponsored by Amgen, J&J, Roche, Sandoz and Hospira. Part of his research is also directly or indirectly sponsored by Amgen, Roche and Sandoz.
Rights and permissions
About this article
Cite this article
van Meer, P., Kooijman, M., van der Laan, J. et al. The value of non-human primates in the development of monoclonal antibodies. Nat Biotechnol 31, 882–883 (2013). https://doi.org/10.1038/nbt.2709
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt.2709
This article is cited by
-
Image quality of Zr-89 PET imaging in the Siemens microPET Focus 220 preclinical scanner
Molecular Imaging and Biology (2016)